Celltrion announced on the 24th that it will attend the ‘2024 American College of Gastroenterology (ACG)’ held in Pennsylvania, USA, from the 25th to the 30th (local time) to present the global Phase 3 clinical trial results of the autoimmune disease treatment new drug Jimpendra and promote the product’s excellence.
ACG is one of the major gastroenterology-related academic conferences in the United States with a history of over 90 years, where gastroenterology experts from around the world gather to share the latest research and clinical information. In particular, Celltrion plans for Chairman Seo Jung-jin to personally attend this conference and actively promote the therapeutic efficacy and competitiveness of Celltrion’s autoimmune disease treatments, including Jimpendra, to key global gastroenterology doctors.
Celltrion has commercialized and supplied tumor necrosis factor (TNF)-alpha (α) inhibitors such as Jimpendra, which has secured new drug status in the US market, as well as Remsima and Uplima. Furthermore, the company is expanding its scope with a mechanism that inhibits interleukin (IL) proteins to treat autoimmune diseases, having obtained domestic and international approvals for Stekima (CT-P43) and currently proceeding with global approval procedures for Actemra biosimilar CT-P47. Global clinical trials for another IL inhibitor, Cosentyx biosimilar CT-P55, are also actively underway.
A Celltrion official stated, “Celltrion has established one of the largest autoimmune disease antibody treatment lineups in the global market and is strengthening its position by competing on an equal footing with global big pharma in this field,” adding, “Through participation in the ACG conference, we will promote the excellence of our products such as Jimpendra and expand communication with global experts to increase prescriptions and market share in the US market going forward.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
